Molecules of the Month - Where Are They Now? ...and Other Short Stories

In case you missed August’s business news, here’s a quick recap of five headlines, including an acquisition, three funding rounds, and a notable company closure.

As part of our "Molecules of the Month" and "Molecule Roundup" series of articles, which bring you the most interesting drug discovery molecules published each month, by member request, we have brought together recently highlighted molecules into a single searchable table. This tool allows you to see longer term-industry trends in therapeutic areas, target selection and chemical matter to inspire ideas for your drug discovery pipeline.

In this article, you'll find a curated selection of >70 molecules from August that piqued our interest, highlights of some of our favorites, and explanations of why they're worth watching.

To choose Molecules of the Month for June, our team reviewed hundreds of molecules from thousands of papers, press releases, conference presentations, and other sources. In this article, you'll find a curated selection of over 60 additional molecules from June that piqued our interest, along with highlights of some of our favorites and explanations of why they're worth keeping an eye on.

This summary of September's major clinical updates features FDA approvals, drug withdrawals, anticipated regulatory decisions, notable trial results, new NDA submissions, clinical trial setbacks, and the initiation of new clinical trials.